Global Artificial Pancreas Device System (APDS) Market: Rapid Expansion Projected for 2024

Global Artificial Pancreas Device System (APDS)
Market: Rapid Expansion Projected for 2024
Global Artificial Pancreas Device System (APDS) Market, By Technology
(Threshold Suspended Device Systems, Treat to Range/Control to Range
(TTR/CTR), Treat to Target/ Control to Target (TTR/CTT)), Distribution Channel
(E-commerce, Standalone Retail Shops, Hospitals), End User (Type 1 Diabetic
Patients, Type 2 Diabetic Patients), and Geography - Trends, Analysis and
Forecast till 2024
Eating habits of type 1 diabetes patients is highly curtailed, complemented by regular administration of
insulin. Type 1 diabetes patients require multiple doses of insulin in a day and all-round the year.
Advancements in research and technology has led to commercialization of easy-to-us insulin delivery
systems such as insulin pens, pumps, inhaled insulin, and injectors. Use of syringes to deliver insulin
has become obsolete with the introduction of advanced and easy-to-use insulin delivery systems
mentioned above.
Request For a Sample Copy of This Business Report @
https://www.coherentmarketinsights.com/insight/request-sample/79
Moreover, these systems offer the convenience to self-administer insulin at home. An artificial pancreas
is a novel concept that promises to revolutionize the entire diabetes market. The system automatically
detects glucose level in patient’s blood or plasma and accordingly administers the necessary dosage of
insulin. Medtronic’s MiniMed 670G is one such wearable artificial pancreas. The system is automated
to monitor glucose levels and deliver insulin through an insulin pump attached to the system. The
artificial pancreas system comprises a transmitter, sensor, and insulin pump. This helps in continuous
monitoring and diabetes management at ease.
Market Dynamics
The artificial pancreas device system (APDS) market growth would be mainly driven by increasing
adoption of the highly useful systems the large base of diabetes type 1 patients, further supplemented
by ever increasing incidence of type 1 diabetes. According to the World Health Organization (WHO),
number of diabetes patients worldwide increased from 108 million in 1980 to 422 million in 2014.
According to Juvenile Diabetes Research Foundation (JDRF), there were around 1.5 million type 1
diabetics worldwide in 2015. JDRF funds research in diabetes 1 and the non-profit organization
expected the first artificial pancreas to be commercialized in 2017. According to the Center for Disease
Control and Prevention (CDC), type 1 diabetes accounts for around 5% of the total diagnosed diabetes
cases in adults in the U.S. Developed regions are expected to dominate the artificial pancreas device
system (APDS) market size, as these regions are early adopters of disruptive technologies.
Key companies covered as a part of this study include Medtronic, Medtrum, Tandem Diabetes Care,
Inc., Johnson & Johnson, Beta Bionics, Bigfoot Biomedical, and Insulet Corporation.
Technological advancements to drive growth of the global artificial pancreas device system
(APDS) market
In 2016, the U.S. FDA approved a hybrid closed-loop artificial pancreas device system (APDS)
MiniMed 670G which is an automated system. The continuous glucose monitor in the system
automatically sends signals to the insulin pump to deliver insulin when the glucose level in body goes
beyond the acceptable limit. Thus, there is no need for the user to stimulate the release of insulin every
time the glucose level is abnormal. This provide the user freedom to perform his/her daily activities.
Such advancement in T1D management is expected to be highly preferred by the users and medical
community, leading to higher advocacy to use this device especially among the patient group using
insulin pumps. Moreover, in mid-2018, a study will test a bihormonal “bionic pancreas” system at the
Massachusetts General Hospital (Boston) and Boston University. This would further fuel the Global
Artificial Pancreas Device System (APDS) Market growth and attract more investments.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: [email protected]

Eating habits of type 1 diabetes patients is highly curtailed, complemented by regular administration of insulin. Type 1 diabetes patients require multiple doses of insulin in a day and all-round the year. Advancements in research and technology has led to commercialization of easy-to-us insulin delivery systems such as insulin pens, pumps, inhaled insulin, and injectors. Use of syringes to deliver insulin has become obsolete with the introduction of advanced and easy-to-use insulin delivery systems mentioned above.

Download Report